The standard treatment for most cancers is chemotherapy and surgery. However, for tumors in the brain and spinal cord treatments can be challenging, because they are often difficult to access due to their location and can be very aggressive. Unfortunately, there are limited therapy options for patients with inoperable tumors. The development of chimeric antigen receptor T cells is a promising new type of cancer therapy. CAR T treatment helps the patient’s own body and immune system to target the tumor.
The Thyroid and Thyroid Cancer Research team, or ThyCARE, at the Rogel Cancer Center received the inaugural Endocrine Care Innovation Award from the American Association of Endocrinology.
Andrea Franson, M.D., M.S., received an $800,000 “A” Award grant from Alex’s Lemonade Stand Foundation for Childhood Cancer to translate an approach developed at Rogel Cancer Center into a phase 1 clinical trial for children with high-grade glioma.
As part of our Next Generation series, meet surgeon Calista Harbaugh, M.D., M.Sc. Her research focuses on health care quality and access, finding ways to improve health outcomes in colon and rectal cancers through initiatives that improve quality and innovations to ensure equitable delivery.
As part of our Next Generation series, meet Justin Colacino, Ph.D. His research explores the relationship between pollution and human health, with his lab work examining how everyday exposures to preservatives in food or chemicals in personal care products can impact chronic disease processes.
As part of the Next Generation series, meet Eileen Carpenter, M.D., Ph.D., a gastroenterologist who specializes in diseases of the pancreas. Running single-cell RNA sequencing and spatial transcriptomics on biorepository samples, her lab is working to identify biomarkers to guide therapeutic decisions in pancreatic cancer treatment.
As we look toward the future of cancer survivorship care, it is vitally important to consider the whole patient, which can best be achieved through multidisciplinary care coordination.
Most grants funded through the National Cancer Institute’s Specialized Program of Research Excellence, or SPORE, mechanism focus on a specific disease. But in 2023, a team of Rogel Cancer Center researchers landed one of these high-profile grants around a different theme. Their project centers around radiosensitization: how do specific drugs make radiation more effective in locally advanced pancreas, brain and breast cancers?
Rogel’s Forbes Institute for Cancer Discovery helps fund bold new ideas with big potential to impact cancer treatment. In less than a decade multiple projects are already bearing fruit.
MENU
